PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a

Abstract

This study provides a new theoretical basis for a novel TNBC therapeutic strategy. Simultaneously targeting PDL1 and LDHA, which would combine immunotherapy and metabolically targeted treatments, might shed some light on the treatment of breast cancer, especially TNBC.